Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Botulinum toxin type A is a purified form of botulinum toxin type A used to block acetylcholine release in the treatment of chronic sialorrhea, muscle spasticity, and dystonia, as well as in cosmetic applications. In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.
- Mechanism
- Curator reviewed · 3 references
Botulinum toxin is a 150-kDa molecular weight protein consisting of a light chain (50 kDa) and heavy chain (100 kDa) linked by a single disulfide bond. The crystal structure reveals 3 lobes - the light chain, the amino-terminal portion of the heavy chain, and the carboxyl-terminal portion of the heavy chain.
Botulinum toxin type A blocks neuromuscular transmission on motor or sympathetic nerve terminals, inhibiting the release of acetylcholine. Botulinum toxins have actions on various regions: the neuromuscular junction, autonomic ganglia, and both postganglionic sympathetic and parasympathetic nerve endings. The heavy chain of the toxin binds selectively at the presynaptic surface of cholinergic neurons in an irreversible fashion. After binding, the toxin-receptor complex is transported into the cell by endocytosis. The disulfide bond between the two chains is cleaved and the botulism toxin enters the cytoplasm. The light chain specifically interacts with SNAP-25 in the nerve terminals to block binding of acetylcholine vesicles with the cell membrane. SNAP-25 is required for successful binding and release of acetylcholine from vesicles in nerve endings.
- Primary indication
- Botulinum toxin A is indicated for a variety of conditions, depending on the preparations.Curator reviewed · 37 structured indications
- Formula / weight
- C6760H10447N1743O2010S32 · 900000.0 Da
- First approval
- Canada, 2012 · United States, 1989 · European Union, 2021
- Also known as
- Abobotulinumtoxin-A · AbobotulinumtoxinA · Botulinum A neurotoxin · Botulinum antitoxin type A · Botulinum toxin A
- Code names
- AGN-151607 · AGN 191622 · ANT-1207 · ANT-1401 · ANT-1403 · BMI2006 · CNT 52120 · DWP-450 · JTM201 · MBA-P01 · NT 201
- Brand names
- Botox
- Botox Cosmetic
- Daxxify
- Dysport
- Nuceiva
- Xeomin
Resolves to
What you can answer from here — as of August 29, 2026
Which drugs share a target with Botulinum toxin type A, and which of those have an active Phase 3 trial?